INS and diabetes mellitus: Oliver et al. showed that the use of PPAR-activating molecules (GW501516) in DM leads to the inhibition of the atherosclerotic process and the improvement of the lipid profile (increase in plasma HDL-C and decreased plasma triglyceride, LDL-C and insulin levels) [60,61].